DIRS.INFO The most relevant business & tech news

☆ Here are Friday's biggest analyst calls: Apple, Target, Coinbase, Berkshire Hathaway, Estee Lauder & more
▼ + stars: | 2024-05-03 | by ( Michael Bloom | ) www.cnbc.com time to read: +6 min

JPMorgan upgrades Williams-Sonoma to neutral from underweight JPMorgan said in its upgrade of the stock that the home furnishings category is stabilizing. "We are downgrading shares of EXPE to Mkt Perform from OP with a target price of $145 vs. $165 previously." JPMorgan upgrades Joby to neutral from underweight JPMorgan said its bear thesis has largely played out for the aviation company. Guggenheim reiterates Target as buy Guggenheim said investors should buy the dip in shares of Target . Morgan Stanley downgrades Estee Lauder to equal weight from overweight Morgan Stanley said it sees a slower recovery for shares of Estee Lauder .

Persons: Stifel, Wells, Truist, OLLI, Guggenheim, Tim Cook, William Blair, Amgen, Jefferies, We've, Ari sta, it's, Morgan Stanley downgrades Estee Lauder, Morgan Stanley, Estee Lauder, TD Cowen, Parsons, Bernstein, Oppenheimer, CFRA, Berkshire Hathaway Organizations: RBC, FTAI Aviation, Pacific, Union Pacific, JPMorgan, Williams, WSM, BMO, Bank of America, Apple, Kiniksa Pharmaceuticals, JOBY, Guggenheim, Target, Citi, MCW, Arista, PSN, Avidity, ~$ Locations: Sonoma, EXPE, GEICO

☆ This rare muscle disease play can rally more than 50%, BofA says
▼ + stars: | 2024-05-03 | by ( Alex Harring | ) www.cnbc.com time to read: +2 min

Avidity Biosciences stock has more room to run thanks to the company's pipeline of multiple treatments for rare muscle disorders, according to Bank of America. Avidity has a therapeutic platform — antibody oligonucleotide conjugates — that was well-received at the time it went public in 2020, Meacham said. But shares were hurt by a clinical hold on Avidity's leading program for treating an uncommon muscle disorder, DM1. The program, tested in the Marina trial, recently saw long-term data that has "helped lift that key overhang on the stock," Meacham said. Those catalysts are tied to two other drugs in the muscle disorder space that are expected to report data this year, according to Meacham.

Persons: Geoff Meacham, Meacham Organizations: Biosciences, Bank of America Locations: San Diego, Thursday's

Some companies that are about to report earnings could see a slide in their share prices. With the busiest week of earnings season underway, investors are certainly in for a hectic time. Nearly a third of the companies in the S & P 500 are scheduled to report their earnings this week. CNBC Pro screened the S & P 500 for companies that could see their stocks tumble after earnings. Industrial technology company Rockwell Automation has had its earnings revised downward 29 times in the past three months.

Persons: Myers Squibb, Steve Chesney Organizations: CNBC Pro, Myers, Bristol, Myers Squibb, Rockwell Automation, Gilead Sciences Locations: Bristol, Biopharmaceutical, Gilead

☆ This biotech stock specializing in targeted cancer treatments can surge 50%, Jefferies says
▼ + stars: | 2024-04-17 | by ( Pia Singh | ) www.cnbc.com time to read: +2 min

Nuvalent could be a winning biotech in the world of cancer treatments, according to Jefferies. Analyst Roger Song initiated the clinical-stage biopharmaceutical company with a buy rating and $97 price target, which implies 49.8% potential upside for shares over the next 12 months. "NUVL leverages strong expertise in structure-based chemistry and deep understanding of unmet [patient] needs to develop potentially 'best-in-class' small molecule targeted cancer therapy," Song wrote in a Wednesday note. "We think both candidates poise well in later line and have strong potential to move into frontline treatments." The company posted a fourth-quarter loss that was slightly wider than expected, at 62 cents per share.

Persons: Roger Song, Jefferies Organizations: Jefferies, U.S . Food, Drug Administration, FactSet Locations: U.S

☆ Comeback candidates: Goldman loves these underperforming stocks with strong fundamentals
▼ + stars: | 2024-04-10 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +3 min

Stocks that have missed out on this year's market rally could be solid contenders for a rebound, according to Goldman Sachs. Heading into the second quarter, Goldman searched for buy-rated names in its coverage universe that could win big going forward. Goldman screened for "compounders," which offer investors high financial returns, free cash flow generation, margin expansion and sales growth. Most analysts covering the stock currently have a buy rating assigned to the name, with about 39% upside to the consensus price target, per LSEG. Pfizer stock has slipped 9% this year.

Persons: Goldman Sachs, Goldman, Dan Levy, Levy, Guggenheim, Vamil Divan, Lamb Weston, Jefferies, Rob Dickerson Organizations: Barclays, Pfizer Locations: U.S

☆ These stocks were oversold during this week's sell-off and could be due for a bounce
▼ + stars: | 2024-04-05 | by ( Brian Evans | ) www.cnbc.com time to read: +3 min

We used the CNBC Pro Stock Screener Tool to identify companies that are oversold based on their 14-day relative strength index. The stock is slightly oversold with a 14-day RSI reading of 24.52. Biopharmaceutical firm Biogen also made the list, with a 14-day RSI reading of 29.71. BIIB YTD mountain Biogen stock. Other oversold stocks on the list include Starbucks and Nike .

Persons: McDonald's, Krispy Kreme, Biogen, Wall, Baird, Brian P, Skorney Organizations: Dow Jones Industrial, Federal Reserve, CNBC, Israel, Starbucks, Nike Locations: Latin America

☆ Loads of analysts just hiked price targets for these 6 stocks — giving one 82% upside
▼ + stars: | 2024-04-05 | by ( Ganesh Rao | ) www.cnbc.com time to read: +3 min

Analysts have become more bullish on six stocks from around the world this week, raising their price targets. The price target changes come ahead of the next earnings season covering the first quarter of this year. CNBC Pro screened for global stocks that have received price target upgrades from five or more analysts in the past seven days and have a potential upside of over 25%. MacroGenics Investment banks raised their price target for the biopharmaceutical firm MacroGenics this week, giving the stock upside potential of 83% over the next 12 months. Tuerkcan — one of the most cautious analysts on the stock — has a price target of $22, pointing to upside of 22% for the stock.

Persons: MacroGenics —, Silvan Tuerkcan, Peter Heckmann, DA Davidson, Jared Issacman's, Dan Dolev Organizations: Formula One, Hyundai Motor, CNBC Pro, Leerlink Partners, FactSet, Investment, DA, Visa, MasterCard, U.S, Mizuho Securities, Mar Locations: Korean, Rockville , Maryland, MacroGenics, York

☆ Supreme Court medication abortion case threatens ‘seismic shift’ in FDA drug approval process, experts warn
▼ + stars: | 2024-03-26 | by ( Meg Tirrell | Tierney Sneed | ) edition.cnn.com time to read: +7 min

If the Supreme Court agrees with the appeals court, the approval of mifepristone could be reset to where it stood before 2016, limiting telehealth access to medication abortion and reimplementing other restrictions. “Nevertheless, drug developers invest in new medicines because, if their investments succeed, FDA’s rigorous drug approvals and subsequent regulatory actions are sturdy enough to facilitate reliable returns. “And without necessary investment, drug development would freeze, stifling innovation and limiting treatment options for patients.”Of course, if the Supreme Court upholds the appeals court decision, the most immediate impact would be to mifepristone itself. “It is both my hope and my ‘bet’ that the court doesn’t uphold the 5th Circuit on the standing argument,” Cohen wrote. “But I have learned the Supreme Court is hard to predict much of the time.”

Persons: thalidomide, mifepristone that’s, ”, Daniel Grossman, ” Grossman, ” PhRMA, Glenn Cohen, Dr, Sanjay Gupta, Cohen, ” Cohen Organizations: CNN, Food and Drug, Federal Food, FDA, US, University of California San, Reproductive, Guttmacher Institute, Circuit, Appeals, Pharmaceutical Research, Manufacturers of America, Harvard Law School, CNN Health Locations: Massengill, University of California San Francisco, Texas

☆ AstraZeneca bets on new cancer treatments with $2 billion Fusion Pharma purchase
▼ + stars: | 2024-03-19 | by ( ) www.cnbc.com time to read: +2 min

AstraZeneca said on Tuesday it will buy clinical-stage biopharmaceutical company Fusion Pharmaceuticals Inc for about $2 billion in cash as the Anglo-Swedish drugmaker bets on next-generation cancer treatments. The drugmaker will pay $21 per Fusion share, a premium of more than 97% to the U.S.-listed company's closing price on Monday. Fusion is developing "next-generation" radioconjugates (RCs) to treat cancer. RCs deliver a radioactive isotope directly to cancer cells through precise targeting using molecules and have emerged as a promising modality in cancer treatment over recent years, AstraZeneca said. Radiotherapy and chemotherapy have been the mainstays of cancer treatment for decades.

Persons: AstraZeneca, Susan Galbraith Organizations: Fusion Pharmaceuticals Inc, Amolyt Pharma, AstraZeneca, Fusion, Oncology, U.S . Food, Drug Administration, FDA Locations: Swedish, U.S, radioconjugates

☆ This overlooked corner of women's health could be a $350 billion market opportunity
▼ + stars: | 2024-03-15 | by ( Michelle Fox | ) www.cnbc.com time to read: +5 min

The management consultant estimates the global market potential to treat symptoms ranges from $120 billion to as much as $350 billion globally. "That would apply to women's health in general, and then specifically and acutely to menopause in particular." From 2002 to 2009, hormone therapy claims were reduced by more than 70%, a 2012 study showed. The clinical-stage biopharmaceutical company, which focuses on women's health, has an intravaginal ring hormone therapy that is set to progress to a single Phase 3 study. Last May, the Food and Drug Administration approved Tokyo-based Astellas Pharma's Veozah, also known as fezolinetant, to treat hot flashes.

Persons: Drew Barrymore, Naomi Watts, Anna Pione, Stephanie Faubion, Faubion, Karen Adams, Jefferies, Kaumil Gajrawala, Bayer, Progyny, Sasha Kelemen Organizations: McKinsey, Health, Mayo Clinic Center, Women's Health, Stanford University, Pfizer, Dare, Food and Drug Administration, Vistagen Therapeutics, Gennev, Midi Health, Leerink Partners Locations: U.S, Tokyo

☆ Morgan Stanley's guide to investing in AI as use of the technology spreads
▼ + stars: | 2024-03-14 | by ( Samantha Subin | ) www.cnbc.com time to read: +4 min

Morgan Stanley is offering up alternative ways to play artificial intelligence beyond the usual tech "enablers" that have come to dominate investor attention. A report issued Tuesday entitled "15 Ways to Play AI" anticipates a "broadening out of the AI theme over the remainder of 2024 and into 2025" and notable AI adoption in areas such as gaming, education and biotechnology. The study, an outgrowth of Morgan Stanley's technology, media and telecom investment conference last week, highlights "the Tech Diffusion theme from all angles and all geographies." Against this backdrop, here are some of Morgan Stanley's top picks as AI broadens out: Several popular technology stocks made the list alongside AI mainstays such as Nvidia , Microsoft and Alphabet . Morgan Stanley included workplace management software company Asana on two of its AI lists, one of companies that are likely to get a productivity boost from AI, and another that highlighted "Global Adopters" of AI.

Persons: Morgan Stanley, Morgan, Edward Stanley, —, Stanley, Morgan Stanley's, Oracle, Asana, Baker Hughes, Prologis, AbbVie Organizations: Microsoft, Meta, Edge, Companies, Nvidia, Apple, Baidu, Palantir Technologies Locations: London, Europe, ASAN

☆ Stocks making the biggest moves before the bell: Oracle, Kohl's, Coinbase, Southwest and more
▼ + stars: | 2024-03-12 | by ( Alex Harring | ) www.cnbc.com time to read: +3 min

Oracle posted adjusted earnings per share of $1.41, topping the $1.38 consensus estimate of analysts polled by LSEG. Kohl's — Shares added 2.2% after the retailer reporting an earnings and revenue beat for the fourth quarter. Wells Fargo upgraded the stock to overweight, while raising its price target for shares to $16. Meanwhile, Oppenheimer upgraded its rating to outperform and upped its target price to $12 per share. TD Cowen also raised its price target to $1,560 while keeping its outperform rating, noting its quick increase to incremental bitcoin holdings.

Persons: Asana, Raymond James, Bitdeer, Wells Fargo, Oppenheimer, Canaccord, TD Cowen, —, Sarah Min, Lisa Kailai Han, Michelle Fox Organizations: Oracle, LSEG, Revenue, Southwest Airlines —, Southwest Airlines, Boeing, Technologies, Wall Street Locations: Southwest

☆ Stocks making the biggest moves midday: Southwest, Oracle, 3M, New York Community Bancorp and more
▼ + stars: | 2024-03-12 | by ( Michelle Fox | ) www.cnbc.com time to read: +4 min

Oracle — The database software stock surged 11% and headed for its best day since December 2021 after posting fiscal third-quarter earnings that topped Wall Street's expectations. Asana — The stock shed about 11% after the work management platform issued weak full-year revenue guidance. Asana said to expect revenue between $716 million and $722 million, less than the forecast of $725 million estimated by analysts polled by LSEG. American is expecting an adjusted loss of 15 cents to 35 cents per share, versus a 22 cent loss expected from analysts polled by FactSet. On lost 0.05 Swiss franc per share, while analysts polled by StreetAccount expected On to earn 0.10.

Persons: Oracle, William Brown, Asana, Microstrategy, Canaccord, TD Cowen, Dan Loeb's, StreetAccount, Archer, Daniels, Samantha Subin, Lisa Han, Alex Harring, Sarah Min Organizations: Southwest Airlines —, Boeing, Southwest, Oracle, L3Harris Technologies, LSEG, Wall Street, Boeing —, New York Times, Max, Alaska Airlines, Acadia Pharmaceuticals, American Airlines —, FactSet, Management, Advance, Swiss, Revenue, Daniels, Midland, Daniels Midland, . New York Community Bancorp Locations: .

☆ Single dose of LSD provides immediate, lasting anxiety relief, study says
▼ + stars: | 2024-03-07 | by ( Sandee Lamotte | ) edition.cnn.com time to read: +8 min

CNN —A clinical trial’s encouraging results won US Food and Drug Administration breakthrough therapy status for an LSD formulation to treat generalized anxiety disorder, Mind Medicine Inc. announced Thursday. Generalized anxiety order is characterized by excessive, ongoing thoughts that are difficult to control and interfere with day-to-day activities. Anxiety is one of the most common mental disorders in the US, according to the Anxiety and Depression Association of America. The MM120 study, however, was accomplished without the use of psychotherapy during the session. So that’s a critical difference.”Most adverse effects in the study were rated as mild to moderate by participants, occurring mostly on the day of the study, Karlin said.

Persons: “, ”, Daniel Karlin, MindMed’s MM120, ” Karlin, buspirone —, Karlin, David Nutt, Nutt, Dr, Gabriella Gobbi, Timothy Leary, Richard Alpert, Eddie Adams, Leary, Richard Nixon Organizations: CNN, US Food and Drug Administration, Medicine Inc, Tufts University School of Medicine, FDA, Depression Association of America, Unit, Imperial College London’s, McGill University Health Centre, Canada, Therapeutics, Mental Health, Harvard University, Harvard, League for Spiritual, Woodstock Locations: Boston, United States, Montreal, New York, Vietnam

☆ Stocks making the biggest moves premarket: Super Micro Computer, Deckers Outdoor, Macy's and more
▼ + stars: | 2024-03-04 | by ( Samantha Subin | ) www.cnbc.com time to read: +3 min

Super Micro Computer , Deckers Outdoor — Shares of Super Micro Computer and Deckers Outdoor jumped 12% and 5%, respectively, after S & P Dow Jones Indices said Friday the two companies would be added to the S & P 500 later this month. They will replace Whirlpool and Zion Bancorp, which will move to the S & P MidCap 400 index as of the March 18 open. Macy's — Macy's stock skyrocketed nearly 17% after Arkhouse Management upped its buyout offer for the department store chain to $24 from $21 a share, or about $6.6 billion. Crypto stocks – Companies whose performance is tied to the price of bitcoin rose in premarket trading after the cryptocurrency touched another two-year high . Spirit AeroSystems , Boeing — Shares of the fuselage maker rose nearly 3%.

Persons: Dow, CleanSpark, AeroSystems, Lyft, Morgan Stanley, Li Auto, Piper Sandler, Brian Mullan, — CNBC's Lisa Han, Fred Imbert, Tanaya, Hakyung Kim, Jesse Pound, Michelle Fox Organizations: Micro Computer, Dow Jones, Whirlpool, Zion Bancorp, Arkhouse Management, Apple, European Commission, Marathon, Iris Energy, RBC, Boeing —, Boeing, Max, —, Citi, Li Auto, Li, Mobile

☆ Morgan Stanley thinks this little-known autoimmune biotech stock can surge more than 40%
▼ + stars: | 2024-03-04 | by ( Pia Singh | ) www.cnbc.com time to read: +2 min

Newly public biotech Kyverna Therapeutics could be a blockbuster cell therapy developer for autoimmune disease, according to Morgan Stanley. The stock opened at $34.25, above the initial public offering price of $22 per share, and closed Friday at $27.75. Although the data from KYV-101 is limited, Ulz wrote that he's "highly encouraged given promising results across multiple indications, multiple sites, and in challenging patients." The analyst pointed out that cell therapies have "meaningfully improved" the treatment of B-cell cancers and that multiple therapies are currently approved, increasing the therapies' potential to treat autoimmune diseases. Ingenui-T is a next-generation process in preclinical development for manufacturing autologous anti-CD19 CAR T-cell therapy, and uses the same CAR construct as KYV-101, Kyverna said.

Persons: Morgan Stanley, Michael Ulz, Kyverna, Ulz Organizations: Therapeutics, Nasdaq, autoimmunity Locations: KYV, Kyverna

☆ Stocks making the biggest moves midday: Macy's, Super Micro Computer, Lyft, DoorDash and more
▼ + stars: | 2024-03-04 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +3 min

Super Micro Computer , Deckers Outdoor — The technology firm and athletic footwear designer respectively popped 27% and nearly 3% after S & P Dow Jones Indices announced Friday that the two stocks would be added to the S & P 500 on March 18. Super Micro Computer and Deckers Outdoor will replace Zions Bancorpation and Whirlpool , which will move to the S & P MidCap 400 Index. Macy's — Shares skyrocketed 16% after Arkhouse Management said it and Brigade Capital Management have raised their offer for the department store . DoorDash — Shares jumped more than 5% after RBC upgraded the food delivery company to outperform from sector perform. Lyft — The ride-sharing platform added 6% after RBC upgraded the stock to an outperform rating from sector perform.

Persons: Dow, Zions, —, Lyft, Morgan Stanley, Li, Piper Sandler, Ford, CNBC's Michelle Fox, Alexander Harring, Hakyung Kim, Tanaya Macheel, Yun Li, Jesse Pound, Samantha Subin Organizations: Micro Computer, Dow Jones, Whirlpool, Arkhouse Management, Brigade Capital Management, Apple, European, Miners, Marathon Digital, Cipher Mining, Iris Energy, RBC, Kyverna Therapeutics, Wells, JPMorgan, Ferrari —, Citi, Li Auto, Dutch Bros, American Airlines —, Max Locations: Wells Fargo

☆ Wall Street thinks this revolutionary gut health stock can triple in value
▼ + stars: | 2024-02-27 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +4 min

Just weeks after its initial public offering, Fractyl Health is catching Wall Street's attention as the next potential biopharmaceutical darling. Analysts are highlighting the company's groundbreaking therapies that directly target the gut and pancreas to ultimately induce Type 2 diabetes maintenance and weight loss. "Growing evidence indicates the gut is a core regulator of metabolism, placing gut dysfunction as a root cause of metabolic disease. Indeed, emerging consensus links modern diets to changes in the gut and pancreas that in turn increase an individual's risk of developing Type 2 Diabetes and obesity," Ulz wrote. gut) root cause of disease, could result in a more durable, disease-modifying treatment, differentiated from current, more burdensome (i.e.

Persons: Morgan Stanley, Jason Gerberry, Michael Ulz's, Ulz, Gerberry, Rejuva, America's Gerberry Organizations: Bank of America, Evercore ISI, Fractyl's, Bank, America's Locations: Fractyl

☆ Here are Friday's biggest analyst calls: Rivian, DraftKings, Nio, Fox, Carvana, Pfizer and more
▼ + stars: | 2024-02-23 | by ( Alex Harring | ) www.cnbc.com time to read: +9 min

Here are Friday's biggest calls on Wall Street: UBS double-downgrades Rivian The firm said to sell the electric vehicle maker's stock, joining a growing group of concerned analysts following the company's earnings report. Raymond James upgrades Carvana The investment bank moved Carvana to market perform from underperform following the fourth-quarter earnings results. Guggenheim initiates Pfizer The firm opened coverage of the biopharmaceutical stock with a buy rating and $36 price target. " Rosenblatt initiates Adeia The firm began coverage with a buy rating and $15 price target. Roth MKM initiates CPI Card Group Roth MKM started coverage of the financial technology stock with a buy rating and $40 price target.

Persons: Ross, ROST, Raymond James, EBITDA, 4Q23, Guggenheim, ATNI, Morgan Stanley, Brighthouse, Rosenblatt, Roth MKM, Fred Imbert Organizations: UBS, Barclays, CNBC, Citi, Fox, JV, Ross, Price, Pfizer, DRG, Equitable, JPMorgan, Traction, JPMorgan downgrades Locations: 1Q24, Xperi, 4Q22

☆ These dividend stocks are poised for a rebound, according to BMO
▼ + stars: | 2024-02-21 | by ( Michelle Fox | ) www.cnbc.com time to read: +3 min

Dividend stocks have come under pressure in today's higher interest rate environment as investors have turned to bonds with juicy yields. They all have a next-twelve-months price-to-earnings ratio lower than the index and a dividend yield higher than the index. It has a 4.3% dividend yield and has gained about 1% year to date. Another utility play, Exelon , has a 4% dividend yield and is also up less than 1% so far this year. Lastly, investment banking giant Morgan Stanley has slipped nearly 9% so far this year and has a 4% dividend yield.

Persons: Brian Belski, Belski, Hunter C, Gary, Exelon, Gilead, Morgan Stanley, Ted Pick, — CNBC's Michael Bloom Organizations: BMO Capital Markets, American Electric, American Electric Power, Icahn Capital, Gilead Sciences, Therapeutics Locations: U.S

☆ 'This is the mental health moment': Innovation and M&A are helping to boost these stocks to new heights
▼ + stars: | 2024-02-19 | by ( Michelle Fox | ) www.cnbc.com time to read: +14 min

There's been a lot of chatter about the mental health crisis since the Covid-19 pandemic. Attention to a long-time crisis The mental health crisis is nothing new. However, there has also been a growing awareness and acceptance of mental health illnesses over the past decade, said Canaccord Genuity analyst Richard Close. "There's been recognition that mental health has a significant impact on a person's overall health," he said. "This is the mental health moment," said Dr. Ken Duckworth, NAMI's chief medical officer and author of "You Are Not Alone: The NAMI Guide to Mental Health."

Persons: There's, Covid, Peter Micca, AbbVie, Emraclidine, Myers Squibb, Karuna, Marc Goodman, Canaccord, Richard Close, MacKenzie Scott, Ken Duckworth, NAMI, Deloitte's Micca, William Blair, Myles Minter, Minter, Auvelity, Leerink's Goodman, Ashwani Verma, Verma, Goodman, BioHaven, Cerevel, Neumora, tardive, David Song, BetterHelp, psychedelics Johnson, Johnson, Spravato, Blair's Minter, Axsome, Micca, Michael Bloom Organizations: Institute for Health Metrics, Deloitte, Cerevel Therapeutics, Karuna Therapeutics, Bristol Myers, Leerink Partners, Centers for Disease Control, National Alliance, Mental, Mental Health, Wall Street, Therapeutics, Neumora Therapeutics, UBS, Karuna, Cellular Therapies, Xenon Pharmaceuticals, Neurocrine Biosciences, Acadia Pharmaceuticals, Tema Neuroscience, Axsome Therapeutics, Acadia Healthcare, BetterHelp, CNBC, pharma, Cellular Locations: Covid, Bristol, XEN1101, Acadia, Tema

☆ Stocks making the biggest moves after hours: Chipotle, Snap, Ford, Warner Bros. Discovery and more
▼ + stars: | 2024-02-06 | by ( Brian Evans | ) www.cnbc.com time to read: +2 min

Mercury Systems — Shares of the technology company fell nearly 12% after missing Wall Street estimates in the fiscal second quarter. Viasat — Shares in the communications firm gained more than 5% after Viasat surpassed Wall Street estimates for revenue in the third quarter. The company notched revenue of $1.13 billion while analysts polled by FactSet forecast $1.11 billion. Analysts polled by LSEG expected the company to earn 77 cents per share on revenue of $3.24 billion. Chipotle — Shares added nearly 3% after beating Wall Street estimates on the top and bottom lines in the fourth quarter.

Persons: FactSet, LSEG, Chipotle Organizations: Mercury, Viasat —, Viasat, Wall, FactSet, LSEG, Corp, —, Gilead Sciences, Gilead Sciences — Stock, Ford — Stock, Ford, Disney, Warner Bros, Discovery, Fox Corp, Fox, Warner Bros ., ESPN Locations: Gilead, Gilead Sciences —

☆ AI lobbying spikes nearly 200% as calls for regulation surge
▼ + stars: | 2024-02-02 | by ( Hayden Field | ) www.cnbc.com time to read: +3 min

The spike in AI lobbying comes amid growing calls for AI regulation and the Biden administration's push to begin codifying those rules. Until 2017, the number of organizations that reported AI lobbying stayed in the single digits, per the analysis, but the practice has grown slowly but surely in the years since, exploding in 2023. The data showed a range of industries as new entrants to AI lobbying: Chip companies like AMD and TSMC , venture firms like Andreessen Horowitz, biopharmaceutical companies like AstraZeneca, conglomerates like Disney and AI training data companies like Appen. Organizations that reported lobbying on AI issues last year also typically lobby the government on a range of other issues. In its Request for Information, the Institute specifically asked responders to weigh in on developing responsible AI standards, AI red-teaming, managing the risks of generative AI and helping to reduce the risk of "synthetic content" (i.e., misinformation and deepfakes).

Persons: OpenSecrets, Biden, ByteDance, Andreessen Horowitz, government's, — CNBC's Mary Catherine Wellons, Megan Cassella Organizations: CNBC, Spotify, Samsung, Nvidia, Big Tech, AMD, U.S . Department of Commerce's National Institute of Standards, Technology, NIST Locations: U.S

☆ Stocks making the biggest moves premarket: UPS, General Motors, Whirlpool, Spotify and more
▼ + stars: | 2024-01-30 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +4 min

Pfizer reported adjusted earnings of 10 cents per share, while analysts polled by LSEG expected a loss of 22 cents per share. On the other hand, the company's $14.25 billion revenue was lower than the $14.42 billion consensus estimate. Revenue came in at $24.92 billion versus the $25.43 billion expected from analysts polled by LSEG. F5 — Shares jumped 8% after the cybersecurity company reported an earnings and revenue beat in the fiscal first quarter. The manufacturing services provider reported earnings of $1.30 per share, better than the $1.15 earnings per share forecast from analysts polled by FactSet.

Persons: Batya Levi, Pfizer, LSEG, Jefferies, Sanmina, — CNBC's Michelle Fox, Hakyung Kim, Tanaya Macheel, Sarah Min, Jesse Pound Organizations: UBS, Pfizer, Oppenheimer, United Parcel Service, LSEG, General Motors, GM, JetBlue Airways —, Whirlpool —, FactSet Locations: Masimo, FactSet .

☆ Big pharma is at a crossroads, as J&J, Merck and others prepare to lose heaps of revenue from blockbuster drugs
▼ + stars: | 2024-01-28 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +12 min

Bristol Myers Squibb's Eliquis is a blood thinner used to prevent clotting, to reduce the risk of stroke. Bristol Myers Squibb's Opdivo is an immunotherapy used to treat cancers, including melanoma and lung cancer. Investors will get updates on Merck and Bristol Myers Squibb's plans for the years ahead when they report earnings on Thursday and Friday, respectively. That's unlike generics, which are cheaper copycats of small-molecule drugs like Bristol Myers Squibb's Eliquis. Bristol Myers Squibb is also testing a new form of Opdivo, which is currently administered into a patient's veins.

Persons: Johnson, William Blair, Matt Phipps, Bristol Myers, Johnson's, Merck's Keytruda, J's Stelara, Opdivo, Phipps, biosimilars, Eliquis, Biosimilars, Humira, JB Reed, Samsung's, Piper Sandler, Christopher Raymond, AbbVie, Raymond, Chris Schott, Schott, Robert Davis, Keytruda, Davis, JPMorgan's Schott, Bristol Myers Squibb, George Frey, J, Amgen, J confidentially, Mike Perrone, It's, Anna Moneymaker Organizations: New York Stock Exchange, Johnson, NYSE Big, Bristol Myers Squibb, Merck, Biden, William Blair & Company, CNBC, Guggenheim, Bristol, Leerink Partners, Bloomberg, Getty, Bioepis, JPMorgan, JPMorgan Health Care, Moderna, Bristol Myers, Karuna Therapeutics, Hardy, Huntsman Cancer Institute, University of Utah, Reuters, Teva Pharmaceuticals, Pharma, U.S . Department of Health, Human Services Locations: drugmakers, EY, Europe, U.S, Cambridge , Massachusetts, Arda, EY's Americas, Bristol, Salt Lake City , Utah, Washington , DC

Search resuls for: "Biopharmaceutical"

25 mentions found